ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Defiance Leveraged Long + Income HIMS ETF
5.43
0.0000
成交量：
- -
成交額：
- -
市值：
271.36萬
市盈率：
- -
高：
5.43
開：
5.43
低：
5.43
收：
5.43
52周最高：
28.09
52周最低：
4.63
股本：
50.00萬
流通股本：
50.00萬
量比：
- -
換手率：
- -
股息：
5.56
股息率：
102.40%
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
Hims & Hers(HIMS.US)挖角禮來公關大將！劍指品牌減肥藥新戰場
智通财经
·
昨天
花旗集團上調Hims & Hers Health Inc評級至中性，目標價大幅提升至24美元
美股速递
·
03/10
Hims & Hers Health盤前續升逾2%，諾和諾德旗下明星減肥藥將登陸平台
动脉网
·
03/10
花旗上調Hims & Hers Health(HIMS.US)評級至「中性」 看好諾和諾德協議下的合規溢價
智通财经
·
03/10
3月10日美股成交額前20：HIMS與諾和諾德達成合作，股價大漲逾40%
环球市场播报
·
03/10
BUZZ--美國股票走勢-Hims & Hers、Live Nation、NovaBridge
路透中文
·
03/09
Hims與諾和諾德合作或引發短期逆風——市場快訊
投资观察
·
03/09
FDA官員Makary表示欣慰：Hims將停止宣傳未經批准的複方藥物，轉而通過與諾和諾德新合作銷售FDA批准產品
美股速递
·
03/09
諾和諾德與Hims & Hers達成協議，後者將銷售Wegovy和Ozempic並撤銷訴訟，股價延續漲勢
美股速递
·
03/09
諾和諾德確認將在HIMS & HERS平台上銷售WEGOVY、OZEMPIC產品。
格隆汇
·
03/09
諾和諾德與Hims & Hers達成協議 美國消費者可自費獲取Ozempic注射劑與Wegovy口服/注射製劑
美股速递
·
03/09
諾和諾德：撤回對Hims & Hers的專利侵權訴訟，但保留未來重新起訴權利
美股速递
·
03/09
諾和諾德：Hims & Hers將停止在平台及營銷中推廣複合GLP-1產品
美股速递
·
03/09
諾和諾德就 Hims 出售 Wegovy 和 Ozempic 達成協議，並撤銷訴訟
路透中文
·
03/09
Hims & Hers Health Inc.：計劃在臨床需要時提供複合GLP-1藥物
美股速递
·
03/09
據報導，諾和諾德（Novo Nordisk）與Hims公司的合作關係可能會結束法律糾紛，Hims公司股價隨之大漲
路透中文
·
03/09
Hims & Hers Health股價盤前暴漲37.9%，消息稱諾和諾德將通過其平台銷售減肥藥
美股速递
·
03/09
Hims & Hers Health盤後股價飆升39%，因報道稱禮來與諾和諾德將合作銷售減肥藥
美股速递
·
03/07
據彭博新聞社報導，諾和諾德與 Hims 解決糾紛，將共同銷售肥胖症藥物
路透中文
·
03/07
諾和諾德和HIMS將共同銷售減肥藥，結束雙方的爭端。
格隆汇
·
03/07
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/HIMY/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HIMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIMY\",,,,,undefined,":{"symbol":"HIMY","market":"US","secType":"STK","nameCN":"Defiance Leveraged Long + Income HIMS ETF","latestPrice":5.4272,"timestamp":1773250532553,"preClose":5.4272,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":500000,"shares":500000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"03-11 13:35:32 EDT","open":5.4272,"high":5.4272,"low":5.4272,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1773259200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":5.4272,"sharesOutstanding":450000,"nav":5.39,"aum":2430000,"dividendRate":1.024009,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIMY\",,,,,undefined,":{"symbol":"HIMY","floatShares":500000,"roa":"--","roe":"--","lyrEps":0,"shares":500000,"dividePrice":5.5575,"high":5.4272,"amplitude":0,"preClose":5.4272,"low":5.4272,"week52Low":4.6299,"pbRate":"--","week52High":28.0918,"institutionHeld":0,"latestPrice":5.4272,"eps":0,"divideRate":1.024009,"volume":0,"delay":0,"ttmEps":0,"open":5.4272,"prevYearClose":6.5028,"prevWeekClose":5.4272,"prevMonthClose":5.4272,"prevQuarterClose":6.5028,"fiveDayClose":5.4272,"twentyDayClose":5.4272,"sixtyDayClose":8.922},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HIMY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-01-27","symbol":"HIMY","reason":null,"defaultRemindTime":1769524200000,"announcedDate":"2026-01-26","type":"delisting","dateTimestamp":1769490000000},{"date":"2026-01-21","symbol":"HIMY","amount":0.0727,"announcedDate":"2026-01-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-21","defaultRemindTime":1769005800000,"name":"Defiance Leveraged Long + Income HIMS ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-22","payableDate":"2026-01-21","currency":"USD","dateTimestamp":1768971600000,"payDate":"2026-01-22"},{"date":"2026-01-14","symbol":"HIMY","amount":0.0725,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-14","defaultRemindTime":1768401000000,"name":"Defiance Leveraged Long + Income HIMS ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-15","payableDate":"2026-01-14","currency":"USD","dateTimestamp":1768366800000,"payDate":"2026-01-15"},{"date":"2026-01-07","symbol":"HIMY","amount":0.1045,"announcedDate":"2026-01-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-07","defaultRemindTime":1767796200000,"name":"Defiance Leveraged Long + Income HIMS ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2026-01-07","currency":"USD","dateTimestamp":1767762000000,"payDate":"2026-01-08"},{"date":"2025-12-31","symbol":"HIMY","amount":0.1087,"announcedDate":"2025-12-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-31","defaultRemindTime":1767191400000,"name":"Defiance Leveraged Long + Income HIMS ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-02","payableDate":"2025-12-31","currency":"USD","dateTimestamp":1767157200000,"payDate":"2026-01-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HIMY\",market:\"US\",,,undefined,":[{"executeDate":"2025-09-03","recordDate":"2025-09-03","paymentDate":"2025-09-04","value":0.2607,"currency":"USD"},{"executeDate":"2025-09-10","recordDate":"2025-09-10","paymentDate":"2025-09-11","value":0.3316,"currency":"USD"},{"executeDate":"2025-09-17","recordDate":"2025-09-17","paymentDate":"2025-09-18","value":0.3517,"currency":"USD"},{"executeDate":"2025-09-24","recordDate":"2025-09-24","paymentDate":"2025-09-25","value":0.5051,"currency":"USD"},{"executeDate":"2025-10-01","recordDate":"2025-10-01","paymentDate":"2025-10-02","value":0.5127,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HIMY\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HIMY\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618918759","title":"Hims & Hers(HIMS.US)挖角禮來公關大將！劍指品牌減肥藥新戰場","url":"https://stock-news.laohu8.com/highlight/detail?id=2618918759","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618918759?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 10:22","pubTimestamp":1773195738,"startTime":"0","endTime":"0","summary":"此前，Hims & Hers HealthHims因销售热门减肥药的仿制版本而面临日益增加的法律和监管压力。Hims & Hers Health表示，公司将通过与礼来的主要竞争对手诺和诺德建立新的合作伙伴关系，专注于提供品牌药物。两家公司于周一表示，诺和诺德已同意在Hims & Hers Health平台上销售其王牌药物Ozempic和Wegovy，其中包括备受欢迎的Wegovy口服片剂。同时，诺和诺德将撤回上个月针对Hims & Hers Health提起的诉讼。作为回报，Hims & Hers Health表示将不再为其仿制版诺和诺德药物投放广告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0289739699.SGD","LU2756315318.SGD","LU2361044949.HKD","LU2237438978.USD","LU0354030438.USD","LU1323610961.USD","IE00BWXC8680.SGD","LU0079474960.USD","LU1720051017.SGD","LU0320765992.SGD","LU0097036916.USD","LU1023059063.AUD","LU2089984988.USD","LU2211815571.USD","LU0109391861.USD","LU2456880835.USD","LU2471134796.USD","LU2108987350.USD","LU2361044865.SGD","LU2552382132.HKD","LU2237443895.HKD","IE00BKPKM429.USD","LU0114720955.EUR","LU0061475181.USD","LU2023251221.USD","HIYY","LU2746668974.SGD","LU0225283273.USD","LU2168564222.USD","LU2461242641.AUD","LU1917777945.USD","SG9999014880.SGD","LU0823434583.USD","LU2087625088.SGD","LU0198837287.USD","LU1145028129.USD","SG9999014906.USD","LU0823434740.USD","LU0466842654.USD","LU2111349929.HKD","LU2324357040.USD","LU2750360641.GBP","IE0009355771.USD","IE00BJJMRX11.SGD","IE00BJJMRZ35.SGD","LU0786609619.USD","BK4588","LU1814569148.SGD","LU2462157665.USD","LU2552382058.USD","IE00BJJMRY28.SGD","SG9999001176.SGD","ELIS","LU1551013425.SGD","LU2361045086.USD","LU2417539215.USD","LU0964807845.USD","LU0109394709.USD","LU2089284900.SGD","LU0385154629.USD","LU2089283258.USD","LU1551013342.USD","SGXZ31699556.SGD","BK4196","SGXZ81514606.USD","IE00BJLML261.HKD","LU1974910355.USD","SG9999018865.SGD","LU2271345857.HKD","LU0158827948.USD","SG9999001176.USD","LU0823416689.USD","IE00B1XK9C88.USD","LU2168564495.EUR","LU0417517546.SGD","LU0708995401.HKD","BK4516","LU0787776722.HKD","LU2237443622.USD","LU0353189680.USD","LU1127390331.HKD","LU2028103732.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0203201768.USD","LU0106261372.USD","LU0432979614.USD","LU0689472784.USD","LU1868836591.USD","LU2168564065.EUR","IE00B775H168.HKD","LU0882574055.USD","LU2491050154.USD","HIMS","IE0004445239.USD","LU2360106947.USD","LU2471134879.HKD","LU2471134523.USD","LU0882574139.USD","LU0353189763.USD","LU0122379950.USD","IE00BK4W5M84.HKD","LU1232071149.USD","LU2756315664.SGD","LU1267930730.SGD","LU1069344957.HKD","LU1035775433.USD","LU2896262040.SGD","IE00B2B36J28.USD","LU1983299246.USD","LU0943347566.SGD","LU2491050071.SGD","SG9999015952.SGD","LU0094547139.USD","LU0316494557.USD","LU0203202063.USD","LU1280957306.USD","IE00BFSS7M15.SGD","SG9999017495.SGD","IE00BN29S564.USD","LU0238689110.USD","SG9999015978.USD","SGXZ99366536.SGD","LU0640476718.USD","LU0820562030.AUD","LU1061106388.HKD","LU2213496289.HKD","LU0683600562.USD","SG9999015945.SGD","IE0001KFT4U8.USD","LLYX","IE0005OL40V9.USD","LU2023250330.USD","SG9999015986.USD","LU2265009873.SGD","LU0889565916.HKD","LU1868836757.USD","LU0471298694.HKD","HIMZ","LU2106854487.HKD","BK4534","HIMY","LU2237443465.HKD","BK4007","LU1093756168.USD","LU0006306889.USD","IE0002141913.USD","LU1057294990.SGD","LU1868836914.USD","IE00BJT1NW94.SGD","LU0158827781.USD","LU1629891620.HKD","LU1712237335.SGD","LU0672654240.SGD","LU2023250504.SGD","LU2112291526.USD","SGXZ57979304.SGD","SGXZ51526630.SGD","LU2552382215.SGD","LU1989771016.USD","LU1804176565.USD","HMYY","LLYZ","LU0096364046.USD","LU1548497426.USD","LU2357305700.SGD","LU1064131342.USD","LU2168563687.JPY","LU0256863811.USD","LU2236285917.USD","LU2237443978.SGD","LU1623119135.USD","LU0234572021.USD","LU0256863902.USD","BK4585","IE00BKDWB100.SGD","LU0471298777.SGD","ELIL","LU0354030511.USD","LU0266013472.USD","LU2237443382.USD","LU0323591593.USD","SG9999014898.SGD","SG9999013999.USD","IE00BK4W5L77.USD","LU0210536198.USD","LU2063271972.USD","LU2168564149.EUR","LU0820561909.HKD","LU2602419157.SGD","IE00B4JS1V06.HKD","IE00B7KXQ091.USD","IE00BFSS8Q28.SGD","LU1093756325.SGD","LU0058720904.USD","LU2468319806.SGD","LU1868837136.USD","LU2237443549.SGD","IE0004445015.USD","LU1291159041.SGD","LLII","GB00BDT5M118.USD","LU1868837300.USD","BK4599","LU2746668461.USD","LU2264538146.SGD","LU2471134952.CNY","BK4533","LU1720051108.HKD","BK4581","LU0820561818.USD","LU1988902786.USD","LU1366192091.USD","IE00B1BXHZ80.USD","LU0456855351.SGD","LU2491049909.HKD","SG9999018857.SGD","LU0320765059.SGD","SG9999014914.USD","LU2750360997.AUD"],"gpt_icon":1},{"id":"1126668487","title":"花旗集團上調Hims & Hers Health Inc評級至中性，目標價大幅提升至24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126668487","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126668487?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 18:27","pubTimestamp":1773138443,"startTime":"0","endTime":"0","summary":"花旗集团最新发布的研究报告显示，已将对远程医疗公司Hims & Hers Health Inc的股票评级从\"卖出\"上调至\"中性\"。与此同时，该机构将其目标股价从13.25美元显著调高至24美元，涨幅超过80%。\n此次评级调整反映了花旗对该公司业务发展前景的重新评估。目标价的大幅提升可能基于对公司营收增长、市场份额扩大或盈利能力改善的积极预期。作为专注于男性与女性健康领域的远程医疗服务商，Hims & Hers Health Inc近期在扩大用户基础和优化服务模式方面取得进展，这或是引发机构重新评估其价值的关键因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HMYY","HIMZ","HIMY","BK4196","HIYY","HIMS"],"gpt_icon":0},{"id":"2618217938","title":"Hims & Hers Health盤前續升逾2%，諾和諾德旗下明星減肥藥將登陸平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2618217938","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618217938?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 16:41","pubTimestamp":1773132060,"startTime":"0","endTime":"0","summary":"3月10日消息，美国互联网医疗公司Hims & Hers Health周一股价暴涨超40%，10日盘前续涨2.3%，报22.67美元。原因是诺和诺德宣布将通过Hims平台向美国消费者销售旗下明星减肥药，包括Ozempic和Wegovy注射剂及Wegovy口服片剂，并同步撤回上月提起的专利侵权诉讼。根据双方达成的协议，Hims平台将以诺和诺德自付价格提供这些药物。值得一提的是，诺和诺德此前已将减肥药月费从约1000美元大幅下调至149至299美元区间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031016431197abcc6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031016431197abcc6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","BK4532","HMYY","LU0154236417.USD","HIMZ","HIMS","BK4007","LU1093756325.SGD","NVOX","BK4588","NVOH","BK4585","HIYY","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4196","HIMY","LU1093756168.USD"],"gpt_icon":0},{"id":"2618147987","title":"花旗上調Hims & Hers Health(HIMS.US)評級至「中性」 看好諾和諾德協議下的合規溢價","url":"https://stock-news.laohu8.com/highlight/detail?id=2618147987","media":"智通财经","labels":["executive","rating"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618147987?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 16:07","pubTimestamp":1773130046,"startTime":"0","endTime":"0","summary":"花旗银行在最新的研究报告中对这一合作给予了高度评价，并将其视为 Hims & Hers 发展史上的重要转折点。花旗分析师指出，通过引入官方正版药物，Hims & Hers 成功摆脱了长期困扰其业务模式的合规性阴影与法律风险。这一利好消息在二级市场引发了剧烈反弹，Hims & Hers 的股价在消息公布后的交易时段内一度飙升超过 35%，周一收涨40.79%，报22.16美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,rating","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0052756011.USD","LU0130102774.USD","LU0310800965.SGD","LU2236285917.USD","LU2360032135.SGD","LU0162691827.USD","LU0170899867.USD","LU0648001328.SGD","LU1267930227.SGD","HIMY","BK4599","IE00BSNM7G36.USD","LU1506573853.SGD","BK4566","HIMZ","LU2417539215.USD","LU0320765646.SGD","LU1244550494.USD","BK4007","BK4504","LU2125154935.USD","BK4534","NVOH","LU0128525689.USD","BK4196","BK4588","LU1244550577.SGD","HIYY","HIMS","LU0130517989.USD","LU0072461881.USD","LU0106831901.USD","LU1093756325.SGD","HMYY","LU1366192091.USD","LU2125154778.USD","BK4207","LU1791807156.HKD","LU0098860793.USD","BK4532","LU0980610538.SGD","LU1668664300.SGD","LU0314106906.USD","LU2462157665.USD","LU1244550221.USD","LU0477156953.USD","IE00BZ1G4Q59.USD","BK4559","NVOX","LU1201861249.SGD","LU0154236417.USD","LU2456880835.USD","IE00BKVL7J92.USD","BK4585","LU1162221912.USD","LU1093756168.USD"],"gpt_icon":1},{"id":"2618672446","title":"3月10日美股成交額前20：HIMS與諾和諾德達成合作，股價大漲逾40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672446","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618672446?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 04:48","pubTimestamp":1773089280,"startTime":"0","endTime":"0","summary":"周一美股成交额第1名英伟达收高2.72%，成交313.6亿美元。亿万富豪廖凯原周一再度增持英伟达，将其持股数量翻倍至200万股。 摩尔维持对博通的“买入”评级，将其目标价从462美元上调至470美元，意味着约42%的上涨空间。 此外，3月2日，英伟达宣布投资20亿美元并与Lumentum达成多年战略合作，包括数十亿美元采购高端激光元件的承诺，聚焦AI数据中心光学技术。 该消息公布后，诺和诺德撤销了对该公司的诉讼，标志着双方争端的结束。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqmumf6558599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HIMZ","NVO","LU1093756325.SGD","BK4585","HIMS","BK4588","HMYY","IE00BKVL7J92.USD","BK4007","NVOX","NVOH","HIMY","IE00BZ1G4Q59.USD","HIYY","LU0154236417.USD","BK4599","BK4196","BK4532","LU1093756168.USD"],"gpt_icon":1},{"id":"2618621524","title":"BUZZ--美國股票走勢-Hims & Hers、Live Nation、NovaBridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621524","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618621524?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 21:30","pubTimestamp":1773063020,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4S3ZX1CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRT","NEMG","XOMX","AU","HIYY","LU1894683264.USD","LU0170899867.USD","DTIL","PLD","ITT","SATS","IE00B2Q91V27.USD","XOMO","SLB","AGH","NEM","BARC.UK","UAL","FCEL","COHX","HL","XENE","HIMZ","CAT","HIMY","LITX","NWMX","LU2462611646.USD","AAL","HIMS","NBP","PFE","RAPP","LU0162691827.USD","XOMZ","LU0433182093.SGD","LUV","VRTL","LYV","AALG","HMYY","COP","SATG","CDE","RLMD","DAL"],"gpt_icon":1},{"id":"1162171962","title":"Hims與諾和諾德合作或引發短期逆風——市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1162171962","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162171962?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 20:53","pubTimestamp":1773060828,"startTime":"0","endTime":"0","summary":"早盘8点49分——Hims & Hers Health Inc.股价因诺和诺德终止对其诉讼并达成合作的消息而大幅飙升。根据协议，Hims平台将引入诺和诺德的GLP-1类药物。Truist分析师指出，尽管此举消除了Hims面临的重要法律风险，但合作可能对其短期业务造成冲击。\n作为协议的一部分，Hims将停止销售复合GLP-1药物，而这类药物曾贡献其大部分营收。不过，品牌GLP-1药物的收入持续性显著更高，尤其考虑到Hims的复合药物此前一直面临法律威胁。分析师认为，这一转变可能促使投资者愿意给予Hims更高估值倍数。受此影响，Hims股价在盘前交易中猛涨51%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","HIMY","HIYY","LU1093756325.SGD","LU1093756168.USD","NVOX","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4196","BK4585","HMYY","LU0154236417.USD","NVOH","HIMZ","HIMS","BK4007","BK4588","BK4532"],"gpt_icon":0},{"id":"1109539785","title":"FDA官員Makary表示欣慰：Hims將停止宣傳未經批准的複方藥物，轉而通過與諾和諾德新合作銷售FDA批准產品","url":"https://stock-news.laohu8.com/highlight/detail?id=1109539785","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109539785?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 20:50","pubTimestamp":1773060649,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）官员Makary近日发表声明，对Hims & Hers Health Inc.决定停止推广未经批准的复方药物表示赞赏。该公司将转向通过与新合作伙伴诺和诺德（Novo）建立的合作关系，专门销售获得FDA正式批准的医药产品。\n这一战略调整标志着Hims在合规经营和产品质量管控方面迈出重要一步。通过采用经FDA严格审批的标准化药物，既能保障患者用药安全，又有助于提升企业品牌信誉。与诺和诺德的合作预计将拓宽其合规产品的市场覆盖范围。\n行业观察人士指出，此举可能对在线医疗平台的产品监管合规性产生示范效应。随着监管环境日趋严格，更多企业或将重新评估其复方药物的营销策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMY","HIMS","HMYY","BK4196","HIMZ","HIYY"],"gpt_icon":0},{"id":"1127863922","title":"諾和諾德與Hims & Hers達成協議，後者將銷售Wegovy和Ozempic並撤銷訴訟，股價延續漲勢","url":"https://stock-news.laohu8.com/highlight/detail?id=1127863922","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127863922?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 20:39","pubTimestamp":1773059964,"startTime":"0","endTime":"0","summary":"Hims & Hers Health Inc. 股价延续上涨态势，此前该公司与丹麦制药巨头诺和诺德达成合作协议，获得销售减肥药Wegovy和糖尿病药物Ozempic的授权。与此同时，诺和诺德已同意撤销对Hims & Hers提起的相关法律诉讼。分析人士指出，此次合作不仅解决了双方的法律纠纷，更为Hims & Hers打开了高达千亿美元的减肥药物市场大门。随着诺和诺德旗下明星产品Wegovy和Ozempic的加入，Hims & Hers的健康服务生态系统将得到进一步完善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMY","HIMS","NVO","HMYY","BK4196","HIMZ","HIYY"],"gpt_icon":0},{"id":"2618356626","title":"諾和諾德確認將在HIMS & HERS平台上銷售WEGOVY、OZEMPIC產品。","url":"https://stock-news.laohu8.com/highlight/detail?id=2618356626","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618356626?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 20:31","pubTimestamp":1773059515,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4532","BK4585","LU1093756168.USD","BK4599","HIMS","LU0154236417.USD","NVO","BK4007","IE00BKVL7J92.USD","NVOH","BK4196","NVOX","HIMZ","HMYY","HIYY","BK4588","HIMY"],"gpt_icon":0},{"id":"1146520715","title":"諾和諾德與Hims & Hers達成協議 美國消費者可自費獲取Ozempic注射劑與Wegovy口服/注射製劑","url":"https://stock-news.laohu8.com/highlight/detail?id=1146520715","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146520715?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 20:31","pubTimestamp":1773059474,"startTime":"0","endTime":"0","summary":"根据最新合作协议，丹麦制药巨头诺和诺德与美国远程医疗平台Hims & Hers Health Inc.将共同为美国消费者开启新型减重疗法通道。消费者可通过自费方式获得诺和诺德旗下三款明星产品：Ozempic注射剂、Wegovy口服片剂及Wegovy注射剂。而Ozempic注射剂与Wegovy注射剂作为经过市场验证的成熟产品，将共同构成完整的体重管理解决方案。对于正在寻找替代传统分销渠道的诺和诺德而言，与Hims & Hers的合作或将开创代谢疾病管理的新范式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HMYY","HIMY","HIYY","HIMS","NVO","HIMZ","BK4196"],"gpt_icon":1},{"id":"1123143091","title":"諾和諾德：撤回對Hims & Hers的專利侵權訴訟，但保留未來重新起訴權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1123143091","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123143091?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 20:31","pubTimestamp":1773059467,"startTime":"0","endTime":"0","summary":"诺和诺德(Novo Nordisk)已正式撤回对数字健康平台Hims & Hers Health Inc.提起的专利侵权诉讼。不过，这家丹麦制药巨头同时明确表示，其保留在未来针对相同事由再次提起诉讼的权利。\n此次诉讼的撤回标志着双方现阶段法律交锋的暂告段落，但诺和诺德此举也为其后续可能采取的法律行动预留了空间。市场分析认为，这反映了诺和诺德在保护其核心产品知识产权方面的持续决心与灵活策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMZ","HMYY","HIMY","NVO","HIYY","HIMS","BK4196"],"gpt_icon":0},{"id":"1174808259","title":"諾和諾德：Hims & Hers將停止在平台及營銷中推廣複合GLP-1產品","url":"https://stock-news.laohu8.com/highlight/detail?id=1174808259","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174808259?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 20:31","pubTimestamp":1773059466,"startTime":"0","endTime":"0","summary":"诺和诺德宣布，数字健康平台Hims & Hers Health Inc.已同意全面停止在其平台及营销材料中推广复合GLP-1受体激动剂产品。这一决定标志着诺和诺德在维护其GLP-1药物市场主导地位方面取得重要进展。\nHims & Hers此前通过线上渠道提供复合版本的GLP-1类药物，这类产品通常未经严格监管审批。此次调整将有助于规范相关疗法市场，确保患者获得经临床验证的正规药物。\n作为全球GLP-1疗法领导者，诺和诺德始终致力于通过法律和技术手段保护其知识产权。该协议也反映出医药行业对数字化医疗平台合规性日益严格的监管趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIYY","HIMZ","HMYY","BK4196","HIMS","HIMY","NVO"],"gpt_icon":0},{"id":"2618381626","title":"諾和諾德就 Hims 出售 Wegovy 和 Ozempic 達成協議，並撤銷訴訟","url":"https://stock-news.laohu8.com/highlight/detail?id=2618381626","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618381626?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 20:30","pubTimestamp":1773059454,"startTime":"0","endTime":"0","summary":"诺和诺德就 Hims 出售 Wegovy 和 Ozempic 达成协议，并撤销诉讼Stine Jacobsen/Maggie Fick. 路透哥本哈根3月9日 - 丹麦制药商诺和诺德NOVb.CO周一表示，已同意通过美国远程医疗公司Hims & Hers的平台销售其重磅Wegovy和Ozempic药物，从而结束了上个月爆发的法律纠纷 。在这项交易之前，美国监管机构上周 ，警告30家远程医疗公司对包括Wegovy和Ozempic在内的GLP-1类复方药物进行误导性促销。诺和诺德表示，它将撤回诉讼，\"同时保留重新提起诉讼的权利\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4S3ZX181:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1629891620.HKD","LU0683600562.USD","LU2417539215.USD","IE00BJLML261.HKD","LU1035775433.USD","IE00BKDWB100.SGD","LU0238689110.USD","LU0079474960.USD","LU0823416689.USD","LU2089284900.SGD","SG9999001176.SGD","LU1323610961.USD","LU0158827948.USD","LU0058720904.USD","HIMY","LU1868837136.USD","LU1720051017.SGD","BK4581","LU2750360997.AUD","LU2896262040.SGD","LU1868837300.USD","SG9999014898.SGD","IE00BJJMRX11.SGD","LU0266013472.USD","LU0354030511.USD","LU1988902786.USD","IE00B1XK9C88.USD","LU0353189763.USD","LU0417517546.SGD","LU1093756168.USD","LU2491050154.USD","SGXZ57979304.SGD","LU2211815571.USD","LU0061475181.USD","LU0225283273.USD","LU0640476718.USD","LU0471298777.SGD","LU0109394709.USD","LU1291159041.SGD","SG9999018857.SGD","LU1064131342.USD","IE00B4R5TH58.HKD","LU2361044865.SGD","SG9999014914.USD","LU2750360641.GBP","HIMS","IE00BFSS7M15.SGD","LU0471298694.HKD","LU1814569148.SGD","IE0009355771.USD","LU2265009873.SGD","LU1989771016.USD","LU0122379950.USD","LU0094547139.USD","LLII","LLYX","LU1023059063.AUD","LU0203202063.USD","LU0097036916.USD","LU2213496289.HKD","LU2237438978.USD","LU0456855351.SGD","LLYZ","IE00B1BXHZ80.USD","SGXZ99366536.SGD","LU1548497426.USD","LU2087625088.SGD","IE0005OL40V9.USD","IE00B7KXQ091.USD","IE00BKPKM429.USD","LU0096364046.USD","LU0820561909.HKD","LU2361044949.HKD","LU2602419157.SGD","BK4585","SG9999015952.SGD","IE0001KFT4U8.USD","LU1551013425.SGD","IE00BK4W5L77.USD","LU1917777945.USD","IE00BWXC8680.SGD","LU2468319806.SGD","SG9999014906.USD","LU0234572021.USD","IE00BJT1NW94.SGD","LU1804176565.USD","LU1720051108.HKD","LU2360106947.USD","LU2746668974.SGD","SG9999013999.USD","LU0006306889.USD","LU0106261372.USD","LU0210536198.USD","BK4588","LU2471134879.HKD","SG9999001176.USD","LU0823434583.USD","LU2112291526.USD","LU2237443895.HKD","LU2462157665.USD","LU1145028129.USD","IE0004445239.USD","IE00BFSS8Q28.SGD","LU2089283258.USD","SG9999015986.USD","LU0354030438.USD","LU2168563687.JPY","LU0289739699.SGD","LU0385154629.USD","GB00BDT5M118.USD","LU1061106388.HKD","LU1232071149.USD","LU2552382215.SGD","LU1868836757.USD","SG9999014880.SGD","IE00BJJMRY28.SGD","LU0964807845.USD","LU2023250330.USD","LU2168564495.EUR","LU0820561818.USD","IE0004445015.USD","LU2552382058.USD","SG9999015978.USD","ELIL","LU2023251221.USD","IE00BK4W5M84.HKD","LU1069344957.HKD","SG9999015945.SGD","LU0882574139.USD","IE00BFTCPJ56.SGD","LU2168564065.EUR","LU0158827781.USD","HIYY","SGXZ51526630.SGD","LU1712237335.SGD","LU1551013342.USD","LU2461242641.AUD","LU0320765059.SGD","LU2471134952.CNY","BK4599","LU1366192091.USD","LU0353189680.USD","LU2111349929.HKD","LU0943347566.SGD","IE00BN29S564.USD","SGXZ31699556.SGD","LU0256863902.USD","LU2361045086.USD","IE00BJJMRZ35.SGD","LU1868836591.USD","LU0689472784.USD","LU2357305700.SGD","BK4190","LU0672654240.SGD","LU0787776722.HKD","LU2089984988.USD","LU2108987350.USD","IE00B2B36J28.USD","LU1267930730.SGD","NVO","LU2746668461.USD","LU0708995401.HKD","LU0323591593.USD","LU2236285917.USD","LU1868836914.USD","LU2264538146.SGD","LU2324357040.USD","BK4534","ELIS","LU2491050071.SGD","LU2106854487.HKD","LU2237443978.SGD","LU1280957306.USD","LU2237443382.USD","LU2237443622.USD","LU2491049909.HKD","LU0432979614.USD","LU0820562030.AUD","LU0882574055.USD","BK4196","LU2471134523.USD","LU2237443465.HKD","LU2028103732.USD","LU0109391861.USD","LU0114720955.EUR","LU0823434740.USD","LU1093756325.SGD","LU0316494557.USD","LU2471134796.USD","LU2756315664.SGD","LU1974910355.USD","IE0002141913.USD","LU2271345857.HKD","BK4516","BK4007","LU2168564222.USD","BK4533","HMYY","HIMZ","LU1623119135.USD","LU0198837287.USD","LU2023250504.SGD","LU2237443549.SGD","LU2063271972.USD","SGXZ81514606.USD","IE00B775H168.HKD","LU2756315318.SGD","LU2456880835.USD","SG9999018865.SGD","LU0320765992.SGD","LU0786609619.USD","LU0256863811.USD","LU0889565916.HKD","LU2168564149.EUR","LU0466842654.USD","SG9999017495.SGD","LU1983299246.USD","LU2552382132.HKD","LU0203201768.USD","LU1127390331.HKD","LU1057294990.SGD","IE00B4JS1V06.HKD"],"gpt_icon":1},{"id":"1130360019","title":"Hims & Hers Health Inc.：計劃在臨床需要時提供複合GLP-1藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=1130360019","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130360019?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 20:30","pubTimestamp":1773059442,"startTime":"0","endTime":"0","summary":"Hims & Hers Health Inc. 宣布，若医疗服务提供者认定复合药物在临床上是必要的，公司计划提供获取复合GLP-1药物的途径。此举旨在根据专业医疗判断，为有特定需求的患者提供更多治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","HIMZ","HMYY","HIYY","HIMS","HIMY"],"gpt_icon":0},{"id":"2618647699","title":"據報導，諾和諾德（Novo Nordisk）與Hims公司的合作關係可能會結束法律糾紛，Hims公司股價隨之大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647699","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647699?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 18:31","pubTimestamp":1773052273,"startTime":"0","endTime":"0","summary":"路透3月9日 - Hims & HersHIMS.N的股价周一盘前交易中上涨了50%以上，此前有报导称，诺和诺德公司NOVOb.CO计划在Hims & Hers的远程保健平台上销售其减肥药物，此举标志着两家公司之间的纠纷有可能结束。周五晚些时候，彭博新闻社报导了 诺和诺德与Hims准备宣布建立新的合作伙伴关系。不过，对Hims的财务影响仍不确定。去年，诺和诺德结束了一项短暂的协议 ，即通过Hims公司销售其Wegovy减肥药，原因是该公司的营销策略和继续销售Wegovy仿制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4T3ZX0YM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMZ","BK4196","HIMS","HMYY","HIYY","HIMY"],"gpt_icon":1},{"id":"1113739733","title":"Hims & Hers Health股價盤前暴漲37.9%，消息稱諾和諾德將通過其平台銷售減肥藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1113739733","media":"美股速递","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113739733?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 16:11","pubTimestamp":1773043863,"startTime":"0","endTime":"0","summary":"远程医疗公司Hims & Hers Health Inc.股价在盘前交易时段飙升37.9%，表现异常强劲。这一显著上涨源于一则市场报告，该报告指出，制药巨头诺和诺德（Novo Nordisk）计划通过Hims & Hers Health的平台销售其广受欢迎的减肥药物。此举被视为对Hims & Hers业务模式的重要认可，并可能为其开辟巨大的新收入来源。投资者对此消息反应热烈，推动公司市值大幅增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HMYY","HIMZ","BK4196","HIYY","HIMS","HIMY"],"gpt_icon":0},{"id":"1157405095","title":"Hims & Hers Health盤後股價飆升39%，因報道稱禮來與諾和諾德將合作銷售減肥藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1157405095","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157405095?lang=zh_tw&edition=fundamental","pubTime":"2026-03-07 08:58","pubTimestamp":1772845133,"startTime":"0","endTime":"0","summary":"受到一则关于制药巨头将联手销售减肥药物的报道提振，Hims & Hers Health Inc.的股价在盘后交易时段录得惊人涨幅，飙升幅度高达39%。\n市场消息称，礼来公司与诺和诺德计划在肥胖症治疗药物领域展开合作，共同进行市场推广与销售。这一重磅合作传闻立即在投资者中引发强烈反响，显示出市场对减肥药市场巨大潜力的高度认可。\n作为一家专注于提供远程医疗服务和个性化健康解决方案的公司，Hims & Hers Health Inc.被市场视为减肥药物需求增长的重要受益者。投资者预期，行业领军企业的强强联合将进一步扩大市场规模，从而为Hims & Hers等相关企业带来显著的业务增长机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","HIMZ","HIYY","HIMS","HMYY","NVO","HIMY"],"gpt_icon":0},{"id":"2617659381","title":"據彭博新聞社報導，諾和諾德與 Hims 解決糾紛，將共同銷售肥胖症藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2617659381","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617659381?lang=zh_tw&edition=fundamental","pubTime":"2026-03-07 08:56","pubTimestamp":1772844999,"startTime":"0","endTime":"0","summary":"据彭博新闻社报导，诺和诺德与 Hims 解决纠纷，将共同销售肥胖症药物路透3月7日 - 据彭博新闻社周五报导，Wegovy生产商诺和诺德NOVOb.CO计划在Hims & Hers HealthHIMS.N平台上销售其肥胖症药物，从而结束两家公司上个月升级为法律战的纠纷。报导援引一位熟悉内情的人士的话说，诺和诺德与Hims计划最快于下周一宣布新的合作关系。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260307:nL4T3ZV00V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMY","BK4196","HIYY","HIMZ","HMYY","HIMS","NVO"],"gpt_icon":0},{"id":"2617262656","title":"諾和諾德和HIMS將共同銷售減肥藥，結束雙方的爭端。","url":"https://stock-news.laohu8.com/highlight/detail?id=2617262656","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617262656?lang=zh_tw&edition=fundamental","pubTime":"2026-03-07 08:34","pubTimestamp":1772843680,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVOX","BK4599","LU1093756168.USD","LU0154236417.USD","BK4588","HIMZ","IE00BZ1G4Q59.USD","HIYY","HIMS","IE00BKVL7J92.USD","NVOH","BK4532","HIMY","NVO","BK4196","BK4585","BK4007","HMYY","LU1093756325.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}]}}